Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTScan Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.50 | -$0.07 | -$0.26 |
| Q2 2024 | 1 | -$0.55 | -$0.07 | -$0.28 |
| Q3 2024 | 1 | -$0.61 | -$0.08 | -$0.32 |
| Q4 2024 | 4 | -$0.35 | -$0.28 | -$0.32 |
| Q1 2025 | 2 | -$0.30 | -$0.25 | -$0.28 |
| Q2 2025 | 1 | -$0.56 | -$0.08 | -$0.29 |
| Q3 2025 | 1 | -$0.57 | -$0.08 | -$0.29 |
| Q4 2025 | 1 | -$0.56 | -$0.08 | -$0.29 |
TScan Therapeutics, Inc. Earnings Date And Information
TScan Therapeutics, Inc. last posted its earnings results on Monday, August 12th, 2024. The company reported $-0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.3 by $0.02. The company had revenue of 1.05 M for the quarter and had revenue of 21.05 M for the year. TScan Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.36 diluted earnings per share) and currently has a price-to-earnings ratio of -3.32. TScan Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based on prior year's report dates.
TScan Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2024 | Q3 2024 | -$0.25 | $1.17 M | $1.05 M | ||
| 08/12/2024 | Q2 2024 | -$0.30 | -$0.28 | 0.02 | $1.80 M | $536,000 |
| 05/13/2024 | Q1 2024 | -$0.25 | -$0.32 | -0.07 | $566,000 | |
| 03/06/2024 | Q4 2023 | -$0.30 | -$0.21 | 0.09 | $7.21 M | |
| 11/09/2023 | Q3 2023 | -$0.43 | -$0.24 | 0.19 | $4.45 M | $3.89 M |
| 08/10/2023 | Q2 2023 | -$0.76 | -$0.51 | 0.25 | $4.37 M | $3.15 M |
| 05/10/2023 | Q1 2023 | -$0.73 | -$0.93 | -0.2 | $6.80 M | |
| 03/08/2023 | Q4 2022 | -$0.73 | -$0.78 | -0.05 | $1,000 | |
| 11/09/2022 | Q3 2022 | -$0.73 | -$0.67 | 0.06 | $3.93 M | $3.36 M |
| 08/10/2022 | Q2 2022 | -$0.76 | -$0.62 | 0.14 | $3.00 M | $4.06 M |
| 05/12/2022 | Q1 2022 | -$0.67 | $3.02 M | |||
| 03/09/2022 | Q4 2021 | -$0.73 | -$0.59 | 0.14 | $2.85 M | |
| 11/10/2021 | Q3 2021 | -$0.68 | -$0.67 | 0.01 | $3.48 M | $2.41 M |
| 08/19/2021 | Q2 2021 | -$2.87 | -$0.45 | 2.42 | $3.37 M | $2.85 M |
| 03/30/2021 | Q1 2021 | -$0.32 | $2.03 M | |||
| 12/31/2020 | Q4 2020 | -$0.33 | $795,000 | |||
| 09/29/2020 | Q3 2020 | -$0.30 | $290,000 | |||
| 06/29/2020 | Q2 2020 | -$0.23 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.23 | $0 |
TScan Therapeutics, Inc. Earnings: FAQ's
When is TScan Therapeutics, Inc.'s earnings date?
TScan Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based off last year's report dates.
Did TScan Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, TScan Therapeutics, Inc. (:TCRX) reported $-0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.3 by $0.02.
How can I listen to TScan Therapeutics, Inc.'s earnings conference
call?
The conference call for TScan Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read TScan Therapeutics, Inc.'s conference call transcript?
The conference call transcript for TScan Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does TScan Therapeutics, Inc. generate each year?
TScan Therapeutics, Inc. (:TCRX) has a recorded annual revenue of $21.05 M.
How much profit does TScan Therapeutics, Inc. generate each year?
TScan Therapeutics, Inc. (:TCRX) has a recorded net income of $21.05 M. TScan Therapeutics, Inc. has generated $-1.36 earnings per share over the last four quarters.
What is TScan Therapeutics, Inc.'s price-to-earnings ratio?
TScan Therapeutics, Inc. (:TCRX) has a price-to-earnings ratio of -3.32 and price/earnings-to-growth ratio is 3.48.